BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34798176)

  • 1. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
    J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
    Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
    JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.
    Kim BK; Tamaki N; Imajo K; Yoneda M; Sutter N; Jung J; Lin T; Tu XM; Bergstrom J; Nguyen K; Nguyen L; Le T; Madamba E; Richards L; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
    J Hepatol; 2022 Dec; 77(6):1482-1490. PubMed ID: 35973577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
    Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
    J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
    Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
    PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
    Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R
    Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
    J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
    Alsaqal S; Hockings P; Ahlström H; Gummesson A; Hedström A; Hulthe J; Johansson L; Niessen HG; Schoelch C; Schultheis C; Vessby J; Wanders A; Rorsman F; Ebeling Barbier C
    J Magn Reson Imaging; 2022 Aug; 56(2):368-379. PubMed ID: 34953171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.
    Chang D; Truong E; Mena EA; Pacheco F; Wong M; Guindi M; Todo TT; Noureddin N; Ayoub W; Yang JD; Kim IK; Kohli A; Alkhouri N; Harrison S; Noureddin M
    Hepatology; 2023 Feb; 77(2):546-557. PubMed ID: 35809234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score.
    Marti-Aguado D; Arnouk J; Liang JX; Lara-Romero C; Behari J; Furlan A; Jimenez-Pastor A; Ten-Esteve A; Alfaro-Cervello C; Bauza M; Gallen-Peris A; Gimeno-Torres M; Merino-Murgui V; Perez-Girbes A; Benlloch S; Pérez-Rojas J; Puglia V; Ferrández-Izquierdo A; Aguilera V; Giesteira B; França M; Monton C; Escudero-García D; Alberich-Bayarri Á; Serra MA; Bataller R; Romero-Gomez M; Marti-Bonmati L
    Liver Int; 2024 Jan; 44(1):202-213. PubMed ID: 37904633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD.
    Torres L; Schuch A; Longo L; Valentini BB; Galvão GS; Luchese E; Pinzon C; Bartels R; Álvares-da-Silva MR
    Ann Hepatol; 2023; 28(1):100774. PubMed ID: 36280013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
    Castera L; Garteiser P; Laouenan C; Vidal-Trécan T; Vallet-Pichard A; Manchon P; Paradis V; Czernichow S; Roulot D; Larger E; Pol S; Bedossa P; Correas JM; Valla D; Gautier JF; Van Beers BE;
    J Hepatol; 2024 Mar; ():. PubMed ID: 38548067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD.
    Dioguardi Burgio M; Sartoris R; Beaufrere A; Grégory J; Guiu B; Guillot C; Rautou PE; Castera L; Bouattour M; Paradis V; Vilgrain V; Ronot M
    Eur Radiol; 2022 Mar; 32(3):1781-1791. PubMed ID: 34533606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Tamaki N; Imajo K; Sharpton S; Jung J; Kawamura N; Yoneda M; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
    Hepatology; 2022 Mar; 75(3):661-672. PubMed ID: 34496054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
    De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
    J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
    Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
    Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
    Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
    JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
    Bertot LC; Jeffrey GP; de Boer B; Wang Z; Huang Y; Garas G; MacQuillan G; Wallace M; Smith BW; Adams LA
    Dig Dis Sci; 2023 Jun; 68(6):2757-2767. PubMed ID: 36947289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.